Plasma Fractionation Market by Application (Hematology, Critical Care, Immunology, Rheumatology), Product (PCC, IVIG, Albumin, Factor VIII, von Willebrand Factor, Protease Inhibitor), End User (Academic Institute, Hospital, Clinic) – 2020 to 2025

$3,850.00$5,850.00

AVAIL 20% DISCOUNT ON PURCHASE OF ANY REPORT
Published on: March 17, 2020
Clear
SKU: GMS-2025 Category:

The market for plasma fractionation is expected to reach USD 37.23 billion by 2025, rising over the forecast period at a CAGR of 6.11%. Increasing use of immunoglobulins in different therapeutic fields, increasing plasma production (and the number of plasma collection centers), and the use of alpha-1-antitrypsin drive the plasma fractionation market.

Plasma Fractionation Market by Application (Hematology, Critical Care, Immunology, Rheumatology), Product (PCC, IVIG, Albumin, Factor VIII, von Willebrand Factor, Protease Inhibitor), End User (Academic Institute, Hospital, Clinic) - 2020 to 2025 1

Plasma Fractionation Market by Application (Hematology, Critical Care, Immunology, Rheumatology), Product (PCC, IVIG, Albumin, Factor VIII, von Willebrand Factor, Protease Inhibitor), End User (Academic Institute, Hospital, Clinic) - 2020 to 2025 2

Plasma Fractionation Market by Application (Hematology, Critical Care, Immunology, Rheumatology), Product (PCC, IVIG, Albumin, Factor VIII, von Willebrand Factor, Protease Inhibitor), End User (Academic Institute, Hospital, Clinic) - 2020 to 2025 3

Plasma Fractionation Market by Application (Hematology, Critical Care, Immunology, Rheumatology), Product (PCC, IVIG, Albumin, Factor VIII, von Willebrand Factor, Protease Inhibitor), End User (Academic Institute, Hospital, Clinic) - 2020 to 2025 4

Plasma Fractionation Market by Application (Hematology, Critical Care, Immunology, Rheumatology), Product (PCC, IVIG, Albumin, Factor VIII, von Willebrand Factor, Protease Inhibitor), End User (Academic Institute, Hospital, Clinic) - 2020 to 2025 5

Plasma Fractionation Market by Application (Hematology, Critical Care, Immunology, Rheumatology), Product (PCC, IVIG, Albumin, Factor VIII, von Willebrand Factor, Protease Inhibitor), End User (Academic Institute, Hospital, Clinic) - 2020 to 2025 6

Plasma Fractionation Market by Application (Hematology, Critical Care, Immunology, Rheumatology), Product (PCC, IVIG, Albumin, Factor VIII, von Willebrand Factor, Protease Inhibitor), End User (Academic Institute, Hospital, Clinic) - 2020 to 2025 7

Plasma Fractionation Market by Application (Hematology, Critical Care, Immunology, Rheumatology), Product (PCC, IVIG, Albumin, Factor VIII, von Willebrand Factor, Protease Inhibitor), End User (Academic Institute, Hospital, Clinic) - 2020 to 2025 8

1 Global Plasma Fractionation Market
1.1 Study Objectives
1.2 Market Definition
1.3 Study Scope
1.3.1 Markets Covered
1.3.2 Geographic Scope

2 RESEARCH METHODOLOGY
2.1 Research Data
2.1.1 Secondary Data
2.1.1.1 Key Data From Secondary Sources
2.1.2 Primary Data
2.1.2.1 Key Data From Primary Sources
2.1.2.2 Key Industry Insights
2.1.2.3 Breakdown of Primaries
2.2 Market Size Estimation
2.2.1 Bottom-Up Approach
2.2.2 Top-Down Approach
2.3 Market Breakdown and Data Triangulation
2.4 Research Assumptions

3 Global Plasma Fractionation Market – Executive Summary
3.1 Market Revenue, Market Size and Key Trends by Company
3.2 Key Trends by type of Application
3.3 Key Trends segmented by Geography

4 Global Plasma Fractionation Market – Comparative Analysis
4.1 Product Benchmarking – Top 10 companies
4.2 Top 5 Financials Analysis
4.3 Market Value split by Top 10 companies
4.4 Patent Analysis – Top 10 companies
4.5 Pricing Analysis

5 Global Plasma Fractionation Market – Industry Market Entry Scenario
5.1 Regulatory Framework Overview
5.2 New Business and Ease of Doing business index
5.3 Case studies of successful ventures
5.4 Customer Analysis – Top 10 companies

6 Global Plasma Fractionation Market – Market Forces
6.1 Introduction
6.2 Market Dynamics
6.2.1 Drivers
6.2.2 Opportunities
6.2.3 Challenges
6.3 Porters Analysis of Market
6.3.1 Bargaining power of suppliers
6.3.2 Bargaining powers of customers
6.3.3 Threat of new entrants
6.3.4 Rivalry among existing players
6.3.5 Threat of substitutes

7 Global Plasma Fractionation Market – Strategic Analysis
7.1 Value Chain analysis
7.2 Product Life Cycle
7.3 Supplier and distributor analysis (Market share and product dealing strategies)

8 Global Plasma Fractionation Market – By Product (Market Size – & million/billion)
8.1 Immunoglobulins
8.2 Coagulation Factor Concentrates
8.3 Protease Inhibitors
8.4 Albumin
8.5 Other

9 Global Plasma Fractionation Market – By Application
9.1 Neurology
9.2 Immunology
9.3 Hematology
9.4 Critical Care
9.5 Pulmonology
9.6 Hemato-Oncology
9.7 Rheumatology
9.8 Other

10 Global Plasma Fractionation Market – By End User
10.1 Hospitals & Clinics
10.2 Clinical Research Laboratories
10.3 Academic Institutes

11 Global Plasma Fractionation Market – By Geography (Market Size – & million/billion)
11.1 Introduction
11.2 North America
11.2.1 US
11.2.2 Canada
11.2.3 Mexico
11.3 Europe
11.3.1 U.K
11.3.2 Germany
11.3.3 Italy
11.3.4 France
11.3.5 Spain
11.3.6 Rest of Europe
11.4 Asia-Pacific
11.4.1 China
11.4.2 Japan
11.4.3 India
11.4.4 South Korea
11.4.5 Rest of APAC
11.5 Rest of the World
11.5.1 South America
11.5.2 Middle East
11.5.3 Africa

12 Global Plasma Fractionation Market – Entropy
12.1 New product launches
12.2 M&A’s, collaborations, JVs and partnerships

13 Global Plasma Fractionation Market Company Profile (Key Players)
13.1 Market Share, Company Revenue, Products, M&A, Developments
13.2 Octapharma
13.3 Grifols
13.4 Shire
13.5 CSL
13.6 China Biologic Products
13.7 Sanquin
13.8 Biotest
13.9 LFB
13.10 Kedrion
13.11 GC Pharma
13.12 Company 11 & more

14 Global Plasma Fractionation Market – Appendix
14.1 Sources
14.2 Abbreviations